Submission of outcome of Board meeting held on 27th May, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals' board approved audited standalone results for Q4 and FY ended 31 March 2025, showing a massive jump in revenue from Rs. 453.12 lakhs in FY24 to Rs. 3,073.44 lakhs in FY25, driven mainly by the new pharma business (Rs. 2,950.95 lakhs) and trading in shares (Rs. 411.52 lakhs). Profit after tax rose from around Rs. 1.04 lakhs to Rs. 8.45 lakhs, with EPS (basic) at Rs. 0.085 for the year. The company's statutory auditor CVS Balachandra Rao & Co issued an unmodified (clean) opinion. The board also appointed V R P S & Co as internal auditor for FY26 and Khushbu Kanwar & Co as secretarial auditor for a five-year term starting April 2025.
The headline revenue and profit jump looks dramatic but is largely off a very small base and was accompanied by sharply negative operating cash flow (Rs. 1,358 lakhs outflow) due to ballooning trade receivables, meaning most sales are still unpaid. Shareholders should note that the company raised fresh capital via share issuance and warrants (Rs. 1,131 lakhs) to fund working capital, and the appointment of new auditors is routine compliance rather than a red flag.